Back to results
US 12,533,369 B2Granted
Mixture of HMOS for improving the microbiota of pregnant women
AssigneeGlycom A/S
InventorsBruce McConnell, Louise Kristine Vigsnæs, Dorthe Seitzberg, Ingvild Dybdrodt Amundsen, Buket Soyyilmaz
Life of this patent
Estimating the term…
Abstract
The invention relates to a human milk oligosaccharide (HMO) for use in supplementing the diet of a pregnant woman, a synthetic composition comprising an HMO for use in supplementing the diet of a pregnant woman, and a method for improving health outcomes in an infant by supplementing the diet of a pregnant woman.
Claims14
A method comprising:
- providing to a woman in pregnancy a composition comprising a predetermined dosage of from about 3 g to about 7 g per day of one or more human milk oligosaccharides (HMOs) chosen from the group consisting of 2′-fucosyllactose (2′-FL), difucosyllactose (DFL), 3-fucosyllactose (3-FL), lacto-N-fucopentaose I (LNFP-I), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), 3′-sialyllactose (3′-SL), 6′-sialyllactose (6′-SL), and combinations thereof, wherein at least one of the one or more HMOs is 2′-FL, the selected dosage of HMOs formulated to modulate the relative abundance of adult-type species of Bifidobacterium in the gut microbiota of the pregnant woman in response to consumption by the pregnant woman;
- providing instructions to the woman to consume the predetermined dosage of the chosen HMOs during the pregnancy;
- and
- in response to consumption of the composition by the pregnant woman during pregnancy, reducing a level of one or more atopic dermatitis symptoms experienced by infant during a predetermined period after birth relative to a median level of said symptoms being experienced during the predetermined period after birth by infants whose mothers did not consume HMOs in pregnancy.
1 more element
A method comprising:
- providing to a woman in pregnancy a composition comprising a predetermined dosage of from about 3 g to about 7 g per day of one or more human milk oligosaccharides (HMOs) chosen from the group consisting of 2′-fucosyllactose (2′-FL), difucosyllactose (DFL), 3-fucosyllactose (3-FL), lacto-N-fucopentaose I (LNFP-I), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), 3′-sialyllactose (3′-SL), 6′-sialyllactose (6′-SL), and combinations thereof, wherein at least one of the one or more HMOs is 2′-FL, the selected dosage of the one or more HMOs formulated to effective to modulate the relative abundance of adult-type species of Bifidobacterium in the gut microbiota of the pregnant woman in response to consumption by the pregnant woman of the composition during the pregnancy;
- providing instructions to the woman to consume the predetermined dosage of the chosen HMOs during pregnancy;
- and
- in response to consumption of the composition by the pregnant woman during pregnancy, reducing a level of one or more gastrointestinal disorder symptoms being experienced by the infant during a predetermined period after birth relative to a median level of said symptoms being experienced during the predetermined period after birth by infants whose mothers did not consume HMOs in pregnancy.
1 more element
A method comprising:
- providing to a woman in pregnancy a composition comprising a predetermined dosage of from about 3 g to about 7 g per day of one or more human milk oligosaccharides (HMOs) chosen from the group consisting of 2′-fucosyllactose (2′-FL), difucosyllactose (DFL), 3-fucosyllactose (3-FL), lacto-N-fucopentaose I (LNFP-I), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), 3′-sialyllactose (3′-SL), 6′-sialyllactose (6′-SL), and combinations thereof, wherein at least one of the one or more HMOs is 2′-FL, the selected dosage of the one or more HMOs formulated to modulate the relative abundance of adult-type species of Bifidobacterium in the gut microbiota of the pregnant woman in response to consumption of the composition by the pregnant woman;
- providing instructions to the woman to consume the predetermined dosage of the chosen HMOs during the initial administration phase beginning;
- and
- in response to consumption of the composition by the pregnant woman during pregnancy, reducing a level of one or more symptoms of infection being experienced by the infant during a predetermined period after birth relative to a median level of said symptoms being experienced during the predetermined period after birth by infants whose mothers did not consume HMOs in pregnancy.
1 more element
Dependencies are inferred from the claim text.